STF-31

• UNSPSC Description:

  STF-31 is a selective inhibitor of glucose transporter 1 (GLUT1), with an IC50 of 1 μM. STF-31 is also a NAMPT inhibitor. STF-31 inhibits glucose uptake in renal cell carcinoma (RCC) 4 cells[1][2].

• Target Antigen:

  Autophagy; GLUT

• Type:

  Reference compound

• Related Pathways:

  Autophagy;Membrane Transporter/Ion Channel

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/STF-31.html

• Purity:

  99.79

• Solubility:

  DMSO : ≥ 34 mg/mL

• Smiles:

  O=C(NC1=CC=CN=C1)C2=CC=C(CNS(=O)(C3=CC=C(C(C)(C)C)C=C3)=O)C=C2

• Molecular Weight:

  423.53

• References & Citations:

  [1]Chan DA, et al. Targeting GLUT1 and the Warburg effect in renal cell carcinoma by chemical synthetic lethality. Sci Transl Med. 2011 Aug 3;3(94):94ra70.|[2]Dedda CD, et al. Pharmacological Targeting of GLUT1 to Control Autoreactive T Cell Responses. International Journal of Molecular Sciences. 2019 Oct 8; 20(19):4962.|[3]Wang L, et al. Glucose transporter 1 critically controls microglial activation through facilitating glycolysis. Molecular Neurodegeneration, 2019 Jan 11; 14(1):2.|[4]Morioka S, et, al. Efferocytosis induces a novel SLC program to promote glucose uptake and lactate release. Nature. 2018 Nov;563(7733):714-718.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  724741-75-7